COVID-19 Clinical Resources and Pertinent Research
A regularly updated list of the most useful COVID-19 clinical resources, the most significant research publications, and reliable news. To contribute, click the plus button on the left. Short URL: bit.ly/C19Res

Vaccines

  1. Vaccine Development
    1. CDC COVID-19 Vaccination Resources (mRNA Vaccine Mechanism Diagram)
    2. Nature – SARS-CoV-2 Vaccines in Development (September 2020) (Pfizer/Moderna vs AZ/Oxford Phase III Diagram)
    3. Vaccine Development Trackers: LSHTM, NYT, STAT News (Vaccine Types Infographic / More Types)
    4. A Guide to Vaccinology: From Basic Principles to New Developments
    5. Maintaining Safety with SARS-CoV-2 Vaccines
    6. ACIP Interim Recommendations for Vaccine Allocation
    7. NEJM: COVID-19 Vaccine Frequently Asked Questions
    8. Important Publications

  2. Pfizer-BioNTech Vaccine (Tozinameran) [Visualization]
    1. FDA Fact Sheet for Healthcare Providers
    2. FDA Fact Sheet for Patients
    3. FDA EUA Letter (Justification Memo)
    4. CDC Clinical Info and Considerations
    5. Phase 3 Trial Data
    6. Efficacy — 94.8% ≥7 Days After Second Dose (52.4% After First Dose, 90.5% ≤ 7 Days After Second Dose: 90.5%); Thus, It Will Take 4 Weeks from the First Vaccine Dose to Develop Robust Protective Immunity (Doses Separated by 3 Weeks / See FDA Briefing Documents)
    7. Special Populations

  3. Moderna Vaccine (mRNA-1273) [Visualization]
    1. FDA Fact Sheet for Healthcare Providers
    2. FDA Fact Sheet for Patients
    3. FDA EUA Letter (Justification Memo)
    4. CDC Clinical Info and Considerations
    5. Phase 3 Trial Data
    6. Efficacy — 94.1% After Second Dose; Thus, It Will Take 6–8 Weeks from the First Vaccine Dose to Develop Robust Protective Immunity (Doses Separated by 4 Weeks / See FDA Briefing Documents)
    7. mRNA-1273 Appears to Reduce Asymptomatic Infections and Transmission By ~67% (See FDA Briefing Addendum)
    8. Special Populations

  4. Oxford–AstraZeneca Vaccine (AZD1222/ChAdOx1 nCoV-19) [Visualization]
    1. Phase 3 Trial Data
Share

Leave a Reply

Your email address will not be published. Required fields are marked *